Maxim raised the firm’s price target on Palisade Bio (PALI) to $8 from $2 and keeps a Buy rating on the shares, citing lower risk as the firm contends that the company’s recent financing supports trials for ‘2108 and potential approval.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI: